Liposomes as delivery systems in the prevention and treatment of infectious diseases

Bergers, Joep J.; Hagen, Timo L.M. ten; Etten, Els W. M. van; Bakker-Woudenberg, Irma A. J. M.

doi:10.1007/bf01875551

Cited by 30 publications

(7 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In these previous studies, the relatively short-acting agent buflomedil hydrochloride (overall half-life 1.9±0.2 h) [30] was applied orally or intravenously, which includes the risk of adverse effects (i.e., headache, vertigo, gastrointestinal discomfort, dizziness) or may cause, at worst, life-threaten-ing complications (i.e., coma, convulsions, respiratory depression) in case of overdose [31,32]. During the last decade, drug delivery via liposomes has become more and more established for systemic as well as topical routes of application [33,34,35,36,37]. In several in vivo studies focusing on topical drug delivery, substances encapsulated into liposomes could be detected in markedly higher concentrations in the dermis and epidermis, whereas much lower plasma concentrations were measured when compared with other applica- tion forms [38,39,40].…”

Section: Discussionmentioning

confidence: 99%

Acceleration of wound healing by topical drug delivery via liposomes

Roesken

Uhl

Curri³

et al. 2000

Langenbeck's Archives of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Acceleration of wound healing by topical drug delivery via liposomes

Roesken

Uhl

Curri³

et al. 2000

Langenbeck's Archives of Surgery

View full text Add to dashboard Cite

show abstract

“…Intramacrophage efficacy of drugs is essential to successful chemotherapy of mycobacteria (1,20). In terms of distribution to intracellular targets and therapeutic efficacy, drugs encapsulated in liposomes have proved to be superior to free antibiotics (1,3,6,15,20,24). Liposomal antibiotics have been used to treat experimental infections caused by intracellular organisms such as MAC (1,6,20,24), Escherichia coli (29), Staphylococcus aureus (11), and Salmonella typhimurium (8).…”

Section: Discussionmentioning

confidence: 99%

Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation

Gómez-Flores

Hsia

Taméz-Guerra

et al. 1996

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The activities of free and liposomal resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex (MAC) grown in broth and in murine peritoneal macrophages were evaluated. Liposomal resorcinomycin A was composed of dimyristoyl phosphatidylcholine and phosphatidylinositol at a molar ratio of 9:1. Both free resorcinomycin A and liposomal resorcinomycin A showed no toxicity to macrophages at concentrations up to 50 micrograms/ml, as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. Minimal inhibitory concentrations of free resorcinomycin A and liposomal resorcinomycin A in broth were 6 and 12 micrograms/ml, respectively, as determined by the MTT colorimetric microassay. In macrophages, liposomal resorcinomycin A caused significantly higher intramacrophage antimycobacterial activity than the free form of the drug. At doses ranging from 6 to 50 micrograms/ml, liposomal resorcinomycin A caused 50 to 93% MAC growth inhibition, respectively (as determined by CFU), while free resorcinomycin A was associated with 33 to 62% MAC growth inhibition, respectively, 3 days after drug treatment. In addition, antimycobacterial activity of liposomal resorcinomycin A in macrophages was maintained 7 days after treatment, whereas the activity of free resorcinomycin A was reduced to negligible 3 days after treatment. In summary, liposome encapsulation of resorcinomycin A resulted in significant enhancement of antibacterial activity against intramacrophagic MAC infection.

show abstract

“…Previously, we have shown that antigens entrapped in liposomes are avidly taken up by macrophages (14). Keeping in view this property of liposomes, we used them for the targeting of CQ to macrophages, which may prove more effective in prophylaxis and therapy of C. neoformans infection.…”

Section: Introductionmentioning

confidence: 98%

“…Liposomes have been proved to be very useful in treatment of macrophage-based intracellular infections (14). Previously, we have shown that antigens entrapped in liposomes are avidly taken up by macrophages (14).…”

Section: Introductionmentioning

confidence: 99%

Prophylactic Role of Liposomized Chloroquine Against Murine Cryptococcosis Less Susceptible to Fluconazole

2004

View full text Add to dashboard Cite

The enhanced prophylactic activity of lip-CQ seems due to rapid uptake of drug-containing liposomes by macrophages. The liposome-mediated accumulation of CQ in macrophages makes the environment unfavorable (alkaline) for the intracellular multiplication of C. neoformans. Moreover, the increased incidence of multi-drug resistance and diversity of pathogenic microorganisms inhibited or killed by CQ makes it the drug of choice for prophylactic therapy.

show abstract

Liposomes as delivery systems in the prevention and treatment of infectious diseases

Cited by 30 publications

References 76 publications

Acceleration of wound healing by topical drug delivery via liposomes

Acceleration of wound healing by topical drug delivery via liposomes

Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation

Prophylactic Role of Liposomized Chloroquine Against Murine Cryptococcosis Less Susceptible to Fluconazole

Contact Info

Product

Resources

About